Introduction {#sec004}
============

Infections remain a significant challenge to solid organ transplant (SOT).\[[@pone.0123706.ref001]\] In the early post transplantation period, SOT recipients are particularly vulnerable to severe bacterial infections due to the complexity of the surgical procedure,\[[@pone.0123706.ref002]\] use of immunosuppression,\[[@pone.0123706.ref003]\] prolonged hospital stay following transplantation,\[[@pone.0123706.ref004]\] exacerbation of pre-existing conditions\[[@pone.0123706.ref005]\] and, less frequently, donor transmitted pathogens.\[[@pone.0123706.ref006]\] Gram negative bacteria (GNs) have become a major concern recently due to the alarming spread of carbapenem resistance.\[[@pone.0123706.ref007]\] Carbapenem-resistant gram negative bacteria (CR-GNs) are particularly concerning because of their difficulty to treat which, in turn, results in significant morbidity and mortality, particularly among SOT recipients.\[[@pone.0123706.ref008]\]

CR-GNs have become particularly common in Italy\[[@pone.0123706.ref009]\]. A recently published report indicates that CR Enterobacteria and CR *Acinetibacter baumannii (A*. *Baumannii)* are endemic in Italy,\[[@pone.0123706.ref007]\] and that over 20% of *Pseudomonas aeruginosa*\[[@pone.0123706.ref010]\] isolates from Italian hospitals are resistant to carbapenems. To date, there have been few publications defining the epidemiology, risk factors and outcomes of CR-GNs in SOT recipients. To assess the impact of these highly resistant bacteria on SOT recipients, the Italian authority for Organ Transplants (*Centro Nazionale Trapianti; CNT*) conducted a nationwide surveillance study.

The objectives of this study were to: describe the epidemiology, assess potential risk factors and assess whether recipients with positive culture(s) to either carbapenem sucesptible GNs or CR-GNs have an increased risk of death at 90 days after SOT

Materials and Methods {#sec005}
=====================

Ethics statement {#sec006}
----------------

DRIn study has been approved by Ethical Committee of the Italian Health Institute (ref CE/13/382) in the framework of the national surveillance programme funded by the Italian Ministry Health. All SOT recipients signed a general consent at the time of inclusion in the waiting list. This informed consent includes acceptance of: policies for management of personal information; transplant and associated procedures; procedures for data collection and data management; policies for organs allocation and system for post-transplant surveillance. A specific consent for this study was not required as: a) information at enrollment were obtained through a mandatory national database (established by law 91/1999) which collects donors and recipients data; b)personal information was anonymized and de-identified prior to analysis; c) no intervention was planned for the purpose of the study and patients underwent medical intervention (including diagnostics) according to clinical guidelines and Italian regulations for safety and quality in solid organ transplantation.

Setting {#sec007}
-------

The CNT coordinates activities at all 44 transplant clinical units in Italy (3 of which perform SOT on pediatric patients only). In 2012 these clinical units performed 2,902 SOT (1,589 kidney, 986 liver, 231 heart, 113 lung and 68 pancreas).

Study design {#sec008}
------------

The study was designed as a cohort based on data from the national surveillance programme established by CNT to assess the burden of GNs after SOT. Patients were considered at risk from the day of transplantation until: a) 90 days thereafter or b) the day of death.

Participant {#sec009}
-----------

Eligible subjects were all recipients aged ≥18 years who received SOT between 15 May and 30 September 2012 in Italy.

Outcomes {#sec010}
--------

[GNs clinical isolate]{.ul}: a) any first GN isolate from any anatomical site; or b) a subsequent GN isolate was considered an additional event only if it was caused by a different GN species. Cultures were performed according to clinical judgment on suspicion of infection. Results of tests performed in asymptomatic subjects for surveillance purpose only (e.g. routine rectal swabs) were not included in the analysis.

[CR-GNs clinical isolate:]{.ul} an event of GNs clinical isolates (as above) due to a GN which is phenotypically resistant to at least one carbapenem.

[Death for all cause within 90 days after transplantation]{.ul}.

Exposure to risk factors {#sec011}
------------------------

Risk analysis for occurrence of clinical isolates with either GNs or CR-GNs was carried out for two groups of risk factors.

[Risk factors represented by recipients' features:]{.ul} sex, age (below or above the median), type of SOT (all considered as individual binary variables as a recipient may receive more than one graft type), duration of hospital stay before SOT (i.e. ≤48h or \> 48h) and duration of hospital stay after SOT (as continuous variable in days).

[Risk factors represented by donors' epidemiological features]{.ul}: sex, age (binary below or above the median), length of stay in ICU (i.e. ≤48h or \> 48h), results of cultures at the donation day (i.e.: negative for GNs, at least one carbapenems susceptible \[CS\] GN isolate or at least one CR-GN isolate), results of cultures during ICU stay (i.e.: negative for GNs, at least one CS GN isolate, at least one CR-GN isolate), signs of sepsis while in ICU (i.e.: no or yes); admission to an ICU where multidrug resistant (MDR) bacteria were reported in the 15 days before donation (i.e.: yes or no).

Analyses for risk of death was carried out for: recipients' features, the results of donors' cultures at the donation day and the occurrence of clinical isolate(s) in recipients (i.e. no infection, infection with a CS-GNs, infection with a CR-GNs).

Data source and microbiological assessment {#sec012}
------------------------------------------

All data were locally collected by clinicians then sent to regional centers and eventually integrated by the CNT which also assessed data for quality and consistency.

Microbiological tests were performed in local laboratories according to national standards consistent with EUCAST criteria.\[[@pone.0123706.ref011]\]

According to the national guidelines\[[@pone.0123706.ref012]\] all donors undergo mandatory blood, urine and respiratory cultures the day of the donation. Donors' tests during ICU stay and all recipients' tests were performed according to clinical judgment.

Statistical analyses {#sec013}
--------------------

Incidence is reported as rate of events per 1000 recipient-days and incidence rate ratio (IRR) is used as measure of association between outcomes and potential risk factors. Confidence intervals are always reported with a 95% level of confidence.

Association between outcomes and potential risk factors was assessed by time adjusted and multivariate mixed-effect Poisson regression model with random intercept.\[[@pone.0123706.ref013]\] Time, as categorical 3-level variable (days 0--30, days 31--60 or days 61--90 after SOT) and duration of hospital stay after SOT, were considered *a priori* confounders in all multivariate analyses.

The best set of events correlation level(s) for each analysis was chosen in order to take inferential models as simple as possible and to facilitate interpretation of results, while preserving the overall robustness of results. According to these principles a specific level of event correlation was considered significant, and thus included in the analysis, only if the p-value for theta = 0 (i.e. no evidence of correlation of events) was \<0.10 at least in null model (i.e. the random intercept model which include the outcome with no independent variable). Laplace approximation\[[@pone.0123706.ref014]\] was used for crossed-effects models. Additional file 1 describes in details how the 3 multilevel models have been set.

The best set of variables for the final multivariate model was chosen according to simplicity and fitness criteria using a stepwise approach. All variables with a IRR \>1.25 or \<0.80 were included in the multivariate model and the fitness of this model was compared with the full model (including all independent variables) by a likelihood ratio test (LRT). The restricted model was kept whenever LRT p-value was \>0.10.

For the analysis of risk of occurrence of GNs clinical isolate(s) in recipients, interaction between all risk factors and time after SOT was assessed by LRT and the association between the outcome and risk factors was presented according to time strata whenever LRT for interaction was \<0.10. Analysis of interaction between time after SOT and risk factors was not undertaken in the analyses for CR-GNs clinical isolates and mortality because of the low number of events.

Medians and interquartile ranges (IQR) were reported for time to the first onset of clinical isolate with either GNs or CR-GNs. Potential differences of median times to the first onset of clinical isolate between recipients with different baseline characteristics were assesses by Kruskal-Wallis test.

STATA 13.1 statistical package was used for all analyses. Results are reported according to the STROBE initiative.\[[@pone.0123706.ref015]\]

Results {#sec014}
=======

Incidence of Gram negative isolates among Italian SOT recipients {#sec015}
----------------------------------------------------------------

Between 15 May and 30 September 2012, 956 subjects underwent SOT in 44 clinical units. Of them 913 were eligible and 887 from 39 clinical units were analyzed (3 units performs transplantation on pediatric recipients only and 2 clinical units were excluded because provided incomplete data; see [Fig 1](#pone.0123706.g001){ref-type="fig"}). Among the enrolled patients, the median age was 53 and 68.9% were male.

![Study flowchart.](pone.0123706.g001){#pone.0123706.g001}

A total of 185 GNs clinical isolates were reported in 147 recipients with a crude incidence rate of 2.39 per 1000 recipient-days (95% CI 2.07--2.77). The most common pathogens were *Escherichia coli* and *Klebsiella* spp. Forty-nine out of 185 (26.5%) isolates were resistant to carbapenems (incidence of CR-GNs 0.63 per 1000 recipient-days; 95%-CI 0.48--0.84). Remarkably the proportion of resistance to carbapenems widely varied between different species ([Table 1](#pone.0123706.t001){ref-type="table"}), with *Klebsiella spp* having the highest proportion of CR-GN isolates (49.1%). On overall 44 recipients died (5.0%) by the 90^th^ day after SOT.

10.1371/journal.pone.0123706.t001

###### Events of infection according the etiology (left columns) and the anatomical site (right columns).

![](pone.0123706.t001){#pone.0123706.t001g}

  **Bacteria**              **Carbapenem phenotype**   ***Anatomical site of isolation*** [^*A*^](#t001fn002){ref-type="table-fn"}                         
  ------------------------- -------------------------- ----------------------------------------------------------------------------- ----- ---- ---- ----- ----
  Klebsiella spp.           27                         26 (49.1%)                                                                    53    9    7    32    12
  A. baumannii              5                          4 (44.4%)                                                                     9     2    5    0     2
  P. aeruginosa             20                         9 (31.0%)                                                                     29    3    15   7     7
  E. coli                   52                         1 (1.9%)                                                                      53    5    7    48    6
  Other enterobacteriacea   18                         2(10.0%)                                                                      20    2    3    12    6
  Other GN                  14                         7(33.3%)                                                                      21    1    8    7     3
  *Total*                   136                        49(26.5%)                                                                     185   22   45   106   36

*Spp*. = *Specie*; *A*. *baumannii* = *Acinetobacter baumannii*; *P*. *aeruginosa* = *Pseudomonas aeruginosa*; *E*. *coli* = *Escherichia coli*; *GN* = gram negative

A\) the same micro-organism may be present in different anatomical site at the time of event diagnosis, secondary involvement of multiple anatomical site was not considered

B\) this includes 12 bile isolates, 7 isolates from surgical site, 8 isolate from skin infection, 3 isolate from peritoneal effusion, 5 isolate form surgical drain (kidney) 1 isolate from faeces.

Time of onset of GNs clinical isolates {#sec016}
--------------------------------------

The median time to the first GNs clinical isolate was 26 days (IQR 16--33; [Table 2](#pone.0123706.t002){ref-type="table"}). As reported in [Fig 2](#pone.0123706.g002){ref-type="fig"}, GNs occurred most frequently in the early post-SOT. Incidence rates were 4.33, 1.67 and 1.14 per 1,000 recipient-days at 0--30, 31--60, and 61--90 days after SOT, respectively.

![Smoothed hazard estimate for ninety days incidence rate of: infection with any gram negative bacteria (blue-dotted line; N = 185); infection with CR GN (yellow-broken line; n = 49); deaths (red-continuous line; N = 44).](pone.0123706.g002){#pone.0123706.g002}

10.1371/journal.pone.0123706.t002

###### Analysis for time to first infection with either any GNs or CR GNs.

![](pone.0123706.t002){#pone.0123706.t002g}

  **Exposure**                                         **Time to infection with any GNs**   **Time to infection with CR GNs**                                                                 
  ---------------------------------------------------- ------------------------------------ ----------------------------------- ----------- ------------- ---- ------ ---------- ------------ ----
  Overall                                                                                   147                                 26          16--33             44     24         14.5--30.5   
  Recipient age                                        ≤53                                  96                                  26          14.5--33.5         35     24         11--28       
  \>53                                                 51                                   26                                  18--32      0.653         9    24     20--34     0.493        
  Recipient sex                                        Female                               47                                  28          20--36             17     26         11--31       
  Male                                                 100                                  24                                  15--32      0.200         27   24     15--28     0.699        
  Kidney [^A^](#t002fn002){ref-type="table-fn"}        No                                   74                                  19.5        10--30             26     20         7--28.       
  Yes                                                  73                                   30                                  21--40      **\<0.001**   18   29     21--38     **0.008**    
  Lung [^A^](#t002fn002){ref-type="table-fn"}          No                                   136                                 25.5        16--32             37     24         15--30       
  Yes                                                  11                                   28                                  25,873      0.446         7    28     11,628     0.860        
  Heart [^A^](#t002fn002){ref-type="table-fn"}         No                                   127                                 28          18--35             40     24.5       16.5--31     
  Yes                                                  20                                   16                                  5.5--21.5   **\<0.001**   4    13.5   6--23      0.137        
  Liver [^A^](#t002fn002){ref-type="table-fn"}         No                                   103                                 27          18--38             29     27         20--34       
  Yes                                                  44                                   22.5                                14--30      **0.042**     15   18     7--26      **0.047**    
  Pancreas [^A^](#t002fn002){ref-type="table-fn"}      No                                   145                                 26          16--32             44     na         na           na
  Yes                                                  2                                    32                                  18--46      0.719         0    na     na         na           
  Hospital stay before SOT                             ≤48h                                 137                                 27          17--34             38     26         18--31       
  \>48h                                                10                                   17.5                                5--19       **0.012**     6    6      2--18      **0.002**    
  Donor age                                            ≤60                                  89                                  25          16--34             26     24.5       15--28       
  \>60                                                 58                                   28                                  18--32      0.532         18   22.5   14--36     0.738        
  Donor sex                                            female                               64                                  27.5        15.5--34           22     27.5       11--31.      
  Male                                                 83                                   24                                  16--33      0.645         22   23     18--28     0.323        
  Donor ICU stay                                       ≤ 48 h                               70                                  26.5        15--34             17     22         11--30       
  \> 48 h                                              77                                   26                                  18--31      0.985         27   24     18--31     0.781        
  Test in ICU [^B^](#t002fn003){ref-type="table-fn"}   no GN                                134                                 25.5        16--34             38     24         15--31       
  CS GN                                                13                                   27                                  23--30      0.769         6    26     7--28      0.656        
  Donation day test                                    no GN                                105                                 26          16--31             30     24         18--30       
  CS GN                                                35                                   25                                  15--36                    12   19.5   8.5--31                 
  CR GN                                                7                                    26                                  18--36      0.935         2    30.5   25--36     0.507        
  Donor sepsis                                         No                                   130                                 25.5        15--33             40     24         14.5--30.5   
  Yes                                                  17                                   26                                  24--30      0.519         4    25.5   18--42.5   0.609        
  ICU with MDR                                         No                                   98                                  26          17--32             28     24         14.5--30.5   
  Yes                                                  49                                   24                                  16--34      0.693         16   24     14--29.5   0.855        

*IQR* = inter-quartile range; *P* = Kruskal--Wallis's p-value; *SOT* = solid organ transplant; *ICU* = intensive care unit; *GN* = gram negative bacteria; *CS* = carbapenems susceptible; *CR* = carbapenems resistant; *MDR* = multi drug resistant organisms.

*A*) "*yes*" if recipient received the specific graft "*no*" if recipient did not (recipients may have received more than one graft at the same time)

*B*) No donor with GN-CR infection while in ICU donated organs.

GNs clinical isolates occurred significantly earlier in heart SOT (median 16 vs. 28 days p\<0.001), liver SOT (median 22.5 vs. 27 days p\<0.042) and in those recipients who had been admitted to hospital for more than 48h before SOT (median 17.5 vs. 27 days p\<0.012). In contrast a delayed onset of GNs was observed among kidney recipients (median 30 vs. 19.5 days; p \< 0.001). Donor characteristics were not associated with the time of the onset of GNs clinical isolates in recipients ([Table 2](#pone.0123706.t002){ref-type="table"}).

Time of onset of CR-GNs clinical isolates {#sec017}
-----------------------------------------

The median time to the first CR-GNs clinical isolate was 24 days (IQR 14.5--30.5; [Table 2](#pone.0123706.t002){ref-type="table"}). As reported in [Fig 2](#pone.0123706.g002){ref-type="fig"}, CR-GNs occurred most frequently in the early post-SOT. Incidence rates were 1.23, 0.51 and 0.16 per 1,000 recipient-days at 0--30, 31--60, and 61--90 days after SOT, respectively.

CR-GNs occurred significantly earlier in liver SOT (median 18 vs. 27 days p = 0.047) and in those recipients who had been admitted to hospital for more than 48h before SOT (median 6 vs. 26 days p = 0.002), whereas CR-GNs occurred significantly later among kidney recipients (median 29 vs. 20 days; p = 0.008). Donor characteristics were not associated with the time of CR-GN onset in recipients ([Table 2](#pone.0123706.t002){ref-type="table"}).

Risk Factors for GNs {#sec018}
--------------------

Time adjusted models provided strong evidence that the incidence of GNs clinical isolates was significantly higher in heart and lung recipients and significantly lower in kidney recipients. Moreover we found a strong direct association between the length of hospital stay after SOT and the risk of being positive to GNs in culture. ([Table 3](#pone.0123706.t003){ref-type="table"})

10.1371/journal.pone.0123706.t003

###### Analysis of the risk of infection with any GNs.

![](pone.0123706.t003){#pone.0123706.t003g}

  **Exposure**                                                        **Descriptive analyses**     **Time adjusted analysis** [^A^](#t003fn002){ref-type="table-fn"} ^,^ [^B^](#t003fn003){ref-type="table-fn"}   **Multivariate analysis** [^A^](#t003fn002){ref-type="table-fn"} ^,^ [^B^](#t003fn003){ref-type="table-fn"} ^,^ [^C^](#t003fn004){ref-type="table-fn"}                                                                                                            
  ------------------------------------------------------------------- ---------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------ ------------------ ---------------------- ---------------------- -------------
  All                                                                 Overall                      887                                                                                                            185                                                                                                                                                      77,260               2.39(2.07--2.77)   \-                 \-                     \-                     \-
  All                                                                 Recipient age≤53             631                                                                                                            119                                                                                                                                                      55,007               2.16(1.81--2.59)   base               \-                     \-                     \-
  Recipient age\>53                                                   256                          66                                                                                                             22,253                                                                                                                                                   2.97(2.33--3.78)     1.24(0.87--1.75)   0.231              \-                     \-                     
  All                                                                 Female recipient             276                                                                                                            61                                                                                                                                                       24,323               2.51(1.95--3.22)   base               \-                     \-                     \-
  Male recipient                                                      611                          124                                                                                                            55,937                                                                                                                                                   2.34(1.96--2.79)     0.93(0.65--1.31)   0.665              \-                     \-                     
  0--30                                                               Without kidney SOT           397                                                                                                            68                                                                                                                                                       11,473               5.93(4.67--7.52)   base               \-                     base                   \-
  With kidney SOT[^**D**^](#t003fn005){ref-type="table-fn"}           490                          45                                                                                                             14,636                                                                                                                                                   3.07(2.30--4.12)     0.46(0.30--0.71)   \<0.001            0.72(0.44--1.18)       0.190                  
  31--60                                                              Without kidney SOT           375                                                                                                            14                                                                                                                                                       11,158               1.25(0.74--2.12)   base               \-                     base                   \-
  With kidney SOT[^**D**^](#t003fn005){ref-type="table-fn"}           486                          29                                                                                                             14,533                                                                                                                                                   2.00(1.39--2.87)     0.83(0.39--1.77)   0.625              1.49(0.74--3.00)       0.264                  
  61--90                                                              Without kidney SOT           370                                                                                                            13                                                                                                                                                       11,000               1.18(0.69--2.04)   base               \-                     base                   \-
  With kidney SOT[^**D**^](#t003fn005){ref-type="table-fn"}           483                          16                                                                                                             14,460                                                                                                                                                   1.11(0.68--1.81)     1.40(0.72--2.75)   0.322              0.97 (0.43--2.17)      0.936                  
  All                                                                 Without lung SOT             853                                                                                                            171                                                                                                                                                      74,632               2.29(1.97--2.66)   base               \-                     base                   \-
  With lung SOT [^**D**^](#t003fn005){ref-type="table-fn"}            34                           14                                                                                                             2,628                                                                                                                                                    5.33(3.16--8.99)     2.56(1.31--5.01)   0.006              **2.01(1.01--4.00)**   **0.045**              
  0--30                                                               Without heart SOT            816                                                                                                            88                                                                                                                                                       24,155               3.64(2.96--4.49)   base               \-                     **base**               \-
  With heart SOT[^**D**^](#t003fn005){ref-type="table-fn"}            71                           25                                                                                                             1,954                                                                                                                                                    12.79(8.65--18.93)   3.56(2.03--6.25)   \<0.001            **2.23(1.20--4.12)**   **0.011**              
  31--60                                                              Without heart SOT            797                                                                                                            42                                                                                                                                                       23,771               1.77(1.31--2.39)   base               \-                     base                   \-
  With heart SOT[^**D**^](#t003fn005){ref-type="table-fn"}            64                           1                                                                                                              1,920                                                                                                                                                    0.52(0.07--3.70)     0.30(0.04--2.28)   0.247              0.29(0.04--2.28)       0.239                  
  61--90                                                              Without heart SOT            789                                                                                                            27                                                                                                                                                       23,626               1.14(0.78--1.67)   base               \-                     base                   \-
  With heart SOT[^**D**^](#t003fn005){ref-type="table-fn"}            64                           2                                                                                                              1,834                                                                                                                                                    1.09(0.27--4.36)     0.98(0.22--4.30)   0.997              0.72(0.15--3.38)       0.673                  
  All                                                                 Without liver SOT            591                                                                                                            130                                                                                                                                                      51,685               2.51(2.12--2.99)   base               \-                     \-                     \-
  With liver SOT [^**D**^](#t003fn005){ref-type="table-fn"}           296                          55                                                                                                             25,575                                                                                                                                                   2.15(1.65--2.80)     0.90(0.62--1.32)   0.607              \-                     \-                     
  All                                                                 Without pancreas SOT         860                                                                                                            183                                                                                                                                                      74,830               2.45(2.12--2.83)   base               \-                     base                   \-
  With pancreas SOT[^**D**^](#t003fn005){ref-type="table-fn"}         27                           2                                                                                                              24,30                                                                                                                                                    0.82(0.21--3.29)     0.36(0.08--1.58)   0.177              0.47(0.11--2.02)       0.306                  
  All                                                                 Hosp. stay before SOT≤48h    842                                                                                                            171                                                                                                                                                      73,771               2.32(2.00--2.69)   base               \-                                            
  Hosp. stay before SOT \>48h                                         45                           14                                                                                                             3,489                                                                                                                                                    4.01(2.37--6.78)     1.88(1.00--3.54)   0.051              1.39(0.74--2.02)       0.306                  
  All                                                                 Hosp. stay after SOT         \-                                                                                                             \-                                                                                                                                                       \-                   \-                 1.02(1.01--1.03)   \<0.001                **1.02(1.01--1.03)**   **\<0.001**
  All                                                                 Donor's age≤60               536                                                                                                            113                                                                                                                                                      46,593               2.43(2.02--2.92)   base               \-                     \-                     \-
  Donor's age \>60                                                    351                          72                                                                                                             30,667                                                                                                                                                   2.35(1.86--2.96)     1.02(0.73--1.45)   0.890              \-                     \-                     
  All                                                                 Female donor                 391                                                                                                            79                                                                                                                                                       34,045               2.32(1.86--2.89)   base               \-                     \-                     \-
  Male donor                                                          496                          106                                                                                                            43,215                                                                                                                                                   2.45(2.03--2.97)     0.99(0.71--1.38)   0.964              \-                     \-                     
  All                                                                 Donor ICU stay≤ 48 h         489                                                                                                            90                                                                                                                                                       43,259               2.08(1.69--2.56)   base               \-                     \-                     \-
  Donor ICU stay \> 48 h                                              398                          95                                                                                                             34,001                                                                                                                                                   2.79(2.29--3.42)     1.18(0.83--1.66)   0.356              \-                     \-                     
  All                                                                 Test in ICU with no GN       804                                                                                                            170                                                                                                                                                      70,088               2.43(2.09--2.82)   base               \-                     \-                     \-
  Test in ICU with CS GN [^**E**^](#t003fn006){ref-type="table-fn"}   83                           15                                                                                                             71,72                                                                                                                                                    2.09(1.26--3.47)     1.03(0.57--1.88)   0.916              \-                     \-                     
  All                                                                 No GN at donation day test   649                                                                                                            134                                                                                                                                                      56,740               2.36(1.99--2.78)   base               \-                     base                   \-
  CS GN at donation day test                                          205                          40                                                                                                             17,707                                                                                                                                                   2.26(1.66--3.06)     1.06(0.71--1.59)   0.777              1.16(0.78--1.73)       0.469                  
  CR GN at donation day test                                          33                           11                                                                                                             2,813                                                                                                                                                    3.91(2.17--7.06)     1.75(0.83--3.67)   0.140              2.00(0.97--4.11)       0.060                  
  All                                                                 Donor without sepsis         792                                                                                                            166                                                                                                                                                      69,089               2.40(2.06--2.80)   base               \-                     \-                     \-
  Donor had sepsis[^**F**^](#t003fn007){ref-type="table-fn"}          95                           19                                                                                                             8,171                                                                                                                                                    2.32(1.48--3.65)     0.98(0.57--1.69)   0.950              \-                     \-                     
  All                                                                 ICU without MDR              663                                                                                                            129                                                                                                                                                      57,842               2.23(1.88--2.65)   base               \-                     \-                     \-
  ICU with MDR[^**G**^](#t003fn008){ref-type="table-fn"}              224                          56                                                                                                             19,418                                                                                                                                                   2.88(2.22--3.75)     1.24(0.85--1.83)   0.267              \-                     \-                     
  \-                                                                  Days 0--30                   887                                                                                                            113                                                                                                                                                      26,109               4.33(3.60--5.20)   \-                 \-                     base                   \-
  Days 31--60                                                         861                          43                                                                                                             25,691                                                                                                                                                   1.67(1.24--2.26)     \-                 \-                 **0.32(0.17--0.59)**   **\<0.001**            
  Days 61--90                                                         853                          29                                                                                                             25,460                                                                                                                                                   1.14(0.79--1.64)     \-                 \-                 **0.27(0.14--0.53)**   **\<0.001**            

*LRT* = likelihood ratio test; *Pop* = Population; *RDR* = recipient-days at risk; *IRR* = incidence rate ratio; *P* = Wald's test p-value; *SOT* = solid organ transplant; *ICU* = intensive care unit; *GNs* = gram negative bacteria; *CS* = carbapenems susceptible; *CR* = carbapenems resistant; *MDR* = multi drug resistant organisms; *na* = not any.

*A*) all analyses are adjusted for correlation of events at the level of clinical units, donors and recipients.

*B*) Risk analysis is provided stratified on the time for risk factors with significant interaction (i.e.: LRT for interaction ≤ 0.100).

*C*) The multivariate model was set through a stepwise forward approach to include variable with IRR\>1.25 or IRR\<0.80, model fitness was assessed by LRT.

*D*) recipients may have received more than one graft at the same time)

*E*) No donor with GN-CR infection while in ICU was admitted to donate organs

*F*) recipient received the graft from a donor who had sepsis any time before donation

*G*) recipient received the graft from a donor who was admitted to admission to an ICU where multidrug resistant (MDR) bacteria were reported in the 15 days before donation.

Time since SOT acted as a strong effect modifier for the risk of being positive to GNs in heart SOT (p for interaction = 0.001) and kidney SOT (p for interaction = 0.008). In fact, in both groups, the variations of IRR were statistically significant in the first month post transplantation only ([Table 3](#pone.0123706.t003){ref-type="table"}). We found no evidence for statistically significant interaction between time after SOT and all other analyzed risk factors.

Multivariate model confirmed all the main findings of the time adjusted models apart from the reduced risk for GNs incidence in kidney SOT. In particular the risk of being positive for GNs increased with: duration of hospital stay after SOT, heart SOT and lung SOT ([Table 3](#pone.0123706.t003){ref-type="table"}).

Estimates of IRRs and other inferential parameters (p-value and 95%CI) were simultaneously adjusted for potential correlation of events at the level of clinical units, donors and recipients (see additional file).

Risk Factors for CR-GNs {#sec019}
-----------------------

Time adjusted models provided strong evidence that the incidence of CR-GNs clinical isolates was significantly higher among lung recipients, those recipients who had been admitted to hospital for more than 48h before SOT and recipients with longer hospital stay after SOT. Multivariate model confirmed all the main findings of the time adjusted models in addition it provided evidence for an increased risk of being positive for CR-GNs in recipients of older donors ([Table 4](#pone.0123706.t004){ref-type="table"}).

10.1371/journal.pone.0123706.t004

###### Analysis of the risk of infection with CR GNs.

![](pone.0123706.t004){#pone.0123706.t004g}

  **Exposure**                                                  **Descriptive analyses**   **Time adjusted analysis**   Multivariate analysis [^*B*^](#t004fn003){ref-type="table-fn"}                                                                                                                                       
  ------------------------------------------------------------- -------------------------- ---------------------------- ---------------------------------------------------------------- ------------------ ---------------------------------------------------------------- --------- ----------------------- ------------- ----
  Overall                                                       887                        49                           77,260                                                           0.63(0.48--0.84)   \-                                                               \-        \-                      \-            
  Recipient age                                                 ≤53                        631                          37                                                               55,007             0.67(0.49--0.93)                                                 base      \-                      base          \-
  \>53                                                          256                        12                           22,253                                                           0.54(0.31--0.95)   0.69(0.33--1.43)                                                 0.318     0.68(0.32--1.42)        0.303         
  Recipient sex                                                 Female                     276                          18                                                               24,323             0.74(0.47--1.17)                                                 base      \-                      \-            \-
  Male                                                          611                        31                           55,937                                                           0.59(0.41--0.83)   0.74 [^***B***^](#t004fn003){ref-type="table-fn"} (0.39--1.43)   0.373     \-                      \-            
  Kidney [^**C**^](#t004fn004){ref-type="table-fn"}             No                         397                          28                                                               33631              0.83(0.57--1.21)                                                 Base      \-                      \-            \-
  Yes                                                           490                        21                           43629                                                            0.48(0.32--0.74)   0.58 [^***B***^](#t004fn003){ref-type="table-fn"} (0.30--1.13)   0.108     \-                      \-            
  Lung [^**C**^](#t004fn004){ref-type="table-fn"}               No                         853                          41                                                               74,632             0.55(0.40--0.75)                                                 base      \-                      **base**      \-
  Yes                                                           34                         8                            2,628                                                            3.04(1.52--6.09)   7.17(2.61--19.65)                                                \<0.001   **5.28(1.89--14.71)**   **0.001**     
  Heart [^**C**^](#t004fn004){ref-type="table-fn"}              No                         816                          45                                                               71552              0.63(0.47--0.84)                                                 base      \-                      \-            \-
  Yes                                                           71                         4                            5708                                                             0.70(0.26--1.87)   0.99(0.31--3.15)                                                 0.993     \-                      \-            
  Liver [^**C**^](#t004fn004){ref-type="table-fn"}              No                         591                          33                                                               51,685             0.63(0.45--0.90)                                                 base      \-                      \-            \-
  Yes                                                           296                        16                           25,575                                                           0.63(0.38--1.02)   0.89(0.45--1.77)                                                 0.742     \-                      \-            
  Pancreas [^**C**^](#t004fn004){ref-type="table-fn"}           No                         860                          49                                                               74,830             0.65(0.49--0.87)                                                 base      \-                      \-            \-
  Yes                                                           27                         0                            2,430                                                            0.00(-)            Na                                                               Na        \-                      \-            
  Hospital stay before SOT                                      ≤48h                       842                          42                                                               73,771             0.57(0.42--0.77)                                                 base      \-                      **base**      \-
  \>48h                                                         45                         7                            3,489                                                            2.01(0.96--4.21)   3.35(1.28--8.75)                                                 0.013     **2.78(1.06--7.25)**    **0.037**     
  Hospital stay after SOT (in days)                             \-                         \-                           \-                                                               \-                 1.03(1.02--1.04)                                                 \<0.001   **1.03(1.02--1.04)**    **\<0.001**   
  Donor age                                                     ≤60                        536                          27                                                               46,593             0.58(0.40--0.84)                                                 base      \-                      **base**      \-
  \>60                                                          351                        22                           30,667                                                           0.72(0.47--1.09)   1.34(0.71--2.51)                                                 0.370     **2.00(1.01--3.98)**    **0.048**     
  Donor sex                                                     female                     391                          25                                                               34,045             0.73(0.50--1.09)                                                 base      \-                      \-            \-
  Male                                                          496                        24                           43,215                                                           0.56(0.37--0.83)   0.74 [^***B***^](#t004fn003){ref-type="table-fn"} (0.40--1.38)   0.344     \-                      \-            
  Donor ICU stay                                                ≤ 48 h                     489                          19                                                               43,259             0.44(0.28--0.69)                                                 base      \-                      base          \-
  \> 48 h                                                       398                        30                           34,001                                                           0.88(0.62--1.26)   1.78(0.93--3.39)                                                 0.082     1.82(0.91--3.68)        0.092         
  Test in ICU[^**D**^](#t004fn005){ref-type="table-fn"}         no GN                      804                          43                                                               70,088             0.61(0.46--0.83)                                                 base      \-                      base          \-
  CS GN                                                         83                         6                            7,172                                                            0.84(0.38--1.86)   1.69(0.63--4.49                                                            1.41(0.49--4.07)        0.529         
  Donation day test                                             no GN                      649                          34                                                               56,740             0.60(0.43--0.84)                                                 base      \-                      base          \-
  CS GN                                                         205                        13                           17,707                                                           0.73(0.43--1.26)   1.27(0.61--2.65)                                                 0.295     1.16(0.53--2.55)        0.717         
  CR GN                                                         33                         2                            2,813                                                            0.71(0.1782.84)    1.22(0.25--6.07)                                                 0.519     1.49(0.30--7.45)        0.624         
  Donor has sepsis [^**E**^](#t004fn006){ref-type="table-fn"}   No                         792                          45                                                               69,089             0.65(0.47--0.87)                                                 base      \-                      base          \-
  Yes                                                           95                         4                            8,171                                                            0.49(0.18--1.30)   0.73(0.24--2.23)                                                           0.68(0.21--2.17)        0.513         
  ICU with MDR [^**F**^](#t004fn007){ref-type="table-fn"}       No                         663                          31                                                               57,842             0.54(0.38--0.76)                                                 base      \-                      base          
  Yes                                                           224                        18                           19,418                                                           0.93(0.58--1.47)   1.62(0.82--3.23)                                                 0.167     1.36(0.68--2.74)        0.384         
  Time after SOT (in days)                                      0--30                      887                          32                                                               26,109             1.23(0.87--1.73)                                                 \-        \-                      **base**      \-
  31--60                                                        861                        13                           25,691                                                           0.51(0.29--0.87)   \-                                                               \-        **0.43(0.22--0.81)**    **0.010**     
  61--90                                                        853                        4                            25,460                                                           0.16(0.06--0.42)   \-                                                               \-        **0.13(0.05--0.38)**    **\<0.001**   

*LRT* = likelihood ratio test; *Pop* = Population; *RDR* = recipient-days at risk; *IRR* = incidence rate ratio; *P* = Wald's test p-value; *SOT* = solid organ transplant; *ICU* = intensive care unit; *GNs* = gram negative bacteria; *CS* = carbapenems susceptible; *CR* = carbapenems resistant; *MDR* = multi drug resistant organisms; *na* = not any.

*A*) all analyses are adjusted for correlation of events at the level of clinical units and recipients.

*B*)The multivariate model was set through a stepwise forward approach to include variable with IRR\>1.25 or IRR\<0.80, model fitness was assessed by LRT.

*C*) "*yes"* if recipient received the graft reported "*no*" if recipient did not (recipients may have received more than one graft at the same time)

*D*) No donor with GN-CR infection while in ICU was admitted to donate organs

*E*) "*yes*" if recipient received the graft from a donor who had sepsis "*no*" if recipient did not

*F*) "*yes*" if recipient received the graft from a donor who was admitted to admission to an ICU where multidrug resistant (MDR) bacteria were reported in the 15 days before donation "*no*" if recipient did not.

Estimates of IRRs and other inferential parameters (p-value and 95%CI) were simultaneously adjusted for potential correlation of events at the level of clinical units and recipients. We found no evidence for potential correlation of events at donors' level (see additional file).

Risk factors associated with 90-day mortality {#sec020}
---------------------------------------------

Time adjusted and multivariate analysis provided evidence that mortality was more than 10 times higher in recipients who had culture(s) positive to CR-GNs after SOT than in those who did not. However, no evidence was found that having received organ(s) from a donor who tested positive to GNs or CR-GNs the donation day was associated to an increased risk of death (see [Table 5](#pone.0123706.t005){ref-type="table"}). Higher rates of mortality were also reported for lung SOT and heart SOT, while a significant reduction of risk of death was found for kidney recipients.

10.1371/journal.pone.0123706.t005

###### Analysis of mortality at 90 days

![](pone.0123706.t005){#pone.0123706.t005g}

  Analysis for 90-day mortality [^*A*^](#t005fn002){ref-type="table-fn"}                                                                                                                    
  ------------------------------------------------------------------------ -------- ----- -------- ------------------ -------------------- --------- ------------------------ ------------- ----
  Overall                                                                           887   44       77,260             0.57(0.42--0.77)     \-        \-                       \-            \-
  GN infection                                                             No       740   25       64,855             0.39(0.26--0.57)     base      \-                       base          \-
  CS                                                                       103      6     9,052    0.66(0.30--1.48)   1.79(0.72--4.45)     0.211     1.31(0.51--3.38)         0.575         
  CR                                                                       44       13    3,353    3.88(2.25--6.68)   11.90(5.77--24.56)   \<0.001   **10.23(4.69--22.31)**   **\<0.001**   
  Recipient age                                                            ≤53      631   30       55,007             0.55 (0.38--0.78)    base      \-                       \-            \-
  \>53                                                                     256      14    22,253   0.63(0.37--1.06)   1.17(0.61--2.23)     0.631     \-                       \-            
  Recipient sex                                                            Female   276   9        24,323             0.37(0.19--0.71)     base      \-                       base          \-
  Male                                                                     611      35    55,937   0.66(0.47--0.92)   1.75(0.83--3.66)     0.138     1.80(0.83--3.92)         0.139         
  Kidney [^**C**^](#t005fn004){ref-type="table-fn"}                        No       397   34       33,631             1.01(0.72--1.41)     base      \-                       base          \-
  Yes                                                                      490      10    43,629   0.23(0.12--0.43)   0.22(0.11--0.46)     \<0.001   **0.43(0.19--0.99)**     **0.047**     
  Lung [^**C**^](#t005fn004){ref-type="table-fn"}                          No       853   38       74,632             0.51(0.37--0.70)     base      \-                       base          \-
  Yes                                                                      34       6     2,628    2.28(1.03--5.08)   4.60(1.85--11.42)    0.001     **3.02(1.05--8.67)**     **0.040**     
  Heart [^**C**^](#t005fn004){ref-type="table-fn"}                         No       816   32       71552              0.45(0.32--0.63)     base      \-                       base          \-
  Yes                                                                      71       12    5708     2.10(1.19--3.70)   5.39(2.57--11.30)    \<0.001   **3.92(1.65--9.31)**     **0.002**     
  Liver [^**C**^](#t005fn004){ref-type="table-fn"}                         No       591   27       51,685             0.52(0.36--0.76)     base      \-                       \-            \-
  Yes                                                                      296      17    25,575   0.66(0.41--1.07)   1.21(0.64--2.31)     0.552     \-                       \-            
  Pancreas [^**C**^](#t005fn004){ref-type="table-fn"}                      No       860   44       74,830             0.59(0.44--0.79)     base      \-                       \-            \-
  Yes                                                                      27       0     2,430    0.00(-)            na(na-na)            na        \-                       \-            
  Hospital stay after SOT (in days)                                        \-       \-    \-       \-                 1.01(1.00--1.03)     0.055     0.99(0.98--1.01)         0.255         
  Hospital stay before SOT                                                 ≤48h     842   36       73,771             0.49(0.35--0.68)     base      \-                       base          \-
  \>48h                                                                    45       8     3,489    2.29(1.15--4.58)   4.45(2.06--10.00)    \<0.001   2.13(0.91--4.97)         0.081         
  Donation day test                                                        no GN    649   32       56,740             0.56(0.40--0.80)     base      \-                       base          \-
  CS GN                                                                    205      9     17,707   0.51(0.26--0.98)   0.88(0.41--1.87)     0.734     1.00(0.46--2.19)         0.995         
  CR GN                                                                    33       3     2,813    1.07(0.34--3.31)   1.89(0.57--6.33)     0.301     1.37(0.39--4.81)         0.627         
  Time after SOT (in days)                                                 0--30    887   26       26,109             1.00(0.67--1.46)     \-        \-                       base          \-
  31--60                                                                   861      8     25,691   0.31(0.16--0.62)   \-                   \-        **0.36(0.16--0.80)**     **0.012**     
  61--90                                                                   853      10    25,460   0.39(0.21--0.73)   \-                   \-        **0.48(0.23--1.01)**     **0.054**     

*LRT* = likelihood ratio test; *Pop* = Population; *RDR* = recipient-days at risk; *IRR* = incidence rate ratio; *P* = Wald's test p-value; *SOT* = solid organ transplant; *ICU* = intensive care unit; *GNs* = gram negative bacteria; *CS* = carbapenems susceptible; *CR* = carbapenems resistant; *MDR* = multi drug resistant organisms; *na* = not any.

*A*) all analyses are adjusted for correlation of events at the level of clinical units.

*B*) The multivariate model was set through a stepwise forward approach to include variable with IRR\>1.25 or IRR\<0.80, model fitness was assessed by LRT;

*C*) "*yes"* if recipient received the graft reported "*no*" if recipient did not (recipients may have received more than one graft at the same time);

Estimates of IRRs and other inferential parameters (p-value and 95%CI) were adjusted for potential correlation of events at the level of clinical units only. We found no evidence for potential correlation of events at donors' level (see additional file).

Discussion {#sec021}
==========

This report presents the results of the largest multicentre surveillance study specifically focused on the incidence of GNs among SOT recipients. GNs clinical isolate were common among SOT recipients in our sample (16.5% of recipients tested positive to GNs at least once with an incidence rate of 2.39 per 1000 day-person). The 26.5% of all GNs isolates were caused by CR-GN bacteria. GNs and CR-GNs occurred early after transplantation (median time to infection of 26 and 24 days, respectively) and all analyses showed a clear decreasing trend form the first to third month after SOT. This time is longer than that expected for bacterial colonization after hospitalization but, in fact, we included in the analysis only clinical isolate form cultures performed on suspicion of infection in symptomatic patients. Recognizing that GNs usually occur soon after transplantation emphasizes that efforts to identify colonization and to prevent transmission should be focused in this early time period after transplantation.

Recipients with positive culture to CR-GNs have a risk 10 times higher to die within 90 days after SOT than those who did not. The spread of CR-GN bacteria is a threat to patients' safety globally. Others have noted the high frequencies and the associated poor outcomes of such CR-GN infections among SOT recipients.\[[@pone.0123706.ref016]\] This study builds on previous findings and provides a call to action for more studies to evaluate methods to limit the spread and to optimize treatment of these challenging infections among SOT recipients. In clinical units with high prevalence of CR-GNs, interventions such as enhanced recipient screening for colonization and/or enhanced isolation in both inpatient and outpatient setting could be studied with the goal of minimizing the transmission of these threatening bacteria.

The incidence of GNs and CR GNs isolates was higher in lung recipients than other SOT recipients. The increased risk of colonization and early infections with GNs in lung recipients is well known and it is potentially due to the interplay of several factors, such as: lung recipients may harbor MDR bacteria well before SOT, having received an allograft which is continuously exposed to the environment, the impaired muco-ciliary clearance, bronchial anastomotic problems, and the colonization of native lung after single-lung transplantation.\[[@pone.0123706.ref017]--[@pone.0123706.ref020]\]

Our study indicated that in the early post transplantation GNs were also frequently isolated among heart recipients. This observation seems to conflict with previously published evidence which indicates that early infections in heart recipients are severe but relatively infrequent events. Though speculative, we believe that this difference might be due to the effect of high antibacterial pressure to which heart recipients are exposed in the peri-transplantation period. In fact, recent published studies suggests that the risk of infection with enterobacteria increases by 4% per day of exposure to antibiotics, such as vancomycin, routinely recommended after cardiac surgery.\[[@pone.0123706.ref015],[@pone.0123706.ref021]\] This hypothesis is also supported by the early onset of GN isolations we have observed. Nevertheless it cannot be excluded that this difference might have occured as we used bacterial isolations rather than infections as the primary outcome of the analysis.

The length of hospital stay either before or after SOT was independently associated with a higher risk for testing positive to CR-GN in cultures. This evidence confirms that hospital environment plays a pivotal role in the transmission of GN bacteria\[[@pone.0123706.ref004],[@pone.0123706.ref015]\] and calls for interventions targeted to minimize the duration of recipients' hospital stay before and (possibly) after SOT.

The only 2 donor dependent risk factors potentially associated with an increased incidence of GNs in recipients were having received organ from a donor who tested positive for CR-GNs the donation day (p = 0.060) and receiving organs form older donors (p = 0.048). Both observation are supported by weak evidence. In addition we could not demonstrate that any donor dependent risk factor was associated with a reduced time to first GNs clinical isolate nor did we carry out a molecular comparison between donors' and recipients' isolates. Therefore the study produces no conclusive evidence about the issue of donor to recipient(s) transmission.

The results of our analyses should be evaluated considering the potential limitations of the study design. The study is based on a passive national surveillance, thus local practices at the clinical unit level may have introduced bias. In fact, clinical units may have different triggers for performing cultures and/or recognizing symptoms of potential infections and as such, under-recognition and under-diagnosis could have occurred; this is less likely in more severe infections which may bias against milder or self-limited infections. The different attitude to carry out cultures may, in part, respond for the strong heterogeneity of GNs incidence between clinical units, thus we decided not to present incidence rates according to the clinical units. The study includes a short time window (138 days) therefore results might, in principle, suffer from seasonal bias or rapidly changing CR-GNs prevalence rates. The data does not include several relevant exposures, such the use of antibiotics, exposure to invasive medical devices and type of immunosuppressive protocols which have been recognized to affect the epidemiology of CR-GN bacteria. In addition to the limitations of the study itself, it must be recognized that the epidemiology of CR-GN bacteria may change rapidly because of novel introductions or effective control measures.

Despite these limitations this study represents the largest, multicenter surveillance to describe the epidemiology and risk factors for GN bacteria in SOT recipients. Even though severe, CR-GNs are, as yet, infrequent in Italian SOT recipients, in spite of the high prevalence of carbapenems resistance throughout the country. The findings of this study suggest that interventions to mitigate the impact of GNs should be directed at measures to reduce the risk of infection in the first 30 days after SOT, to optimize the peri-SOT management of lung and heart recipients and to minimize the exposure of recipients to hospital environment either before or after transplantation.
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======================
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Members of Donor-Recipient Infection DRIn Collaborative Study Group: Daniela Maccarone, Centro Regionale Trapianti Abruzzo, L'Aquila; Bruno Giacon, Ospedale Centrale di Bolzano, Bolzano; Angelo Saracino, Ospedale Madonna delle Grazie, Matera; Pellegrino Mancini, Centro Regionale Trapianti Calabria, Reggio Calabria; Paolo Giannattasio, Centro Regionale Trapianti Campania, Napoli; Gabriela Sangiorgi, Centro Riferimento Trapianti dell'Emilia-Romagna, Bologna; Maurizia Licari, Centro Regionale Trapianti Friuli Venezia Giulia, Udine; Maurizio Valeri, Ospedale S. Camillo, Roma; Montserrat Munoz Lopez, IRCCS San Martino, Genova; Massimo Moschini, Ospedali Riuniti, Ancona; Raffaella Giacometti, Centro Regionale Trapianti Piemonte, Torino; Annarita Panebianco, Centro Regionale Trapianti Puglia, Bari; Roberto Littera, Centro Regionale Trapianti Sardegna, Cagliari; Angelita Butera, Centro Regionale Trapianti Sicilia, Palermo; Manuela Bonizzoli, Azienda Ospedaliero Universitaria Careggi, Firenze; Laura Pilati, Azienda Provinciale per i Servizi Sanitari,Trento; Atanassios Dovas, Struttura di Riferimento Regionale per i Trapianti Regione Umbria, Perugia; Fabio Lazzarini, Centro Regionale Trapianti Veneto, Padova; Elena Coluccio, IRCCS Ospedale Maggiore Policlinico, Milano; Angelo Ghirardini, Centro nazionale Trapianti,Roma.

[^1]: **Competing Interests:**Yehuda Carmeli, received grants, honoraria, travel support, consulting fees, and other forms of financial support. Paolo Antonio Grossi received grants, honoraria, travel support, consulting fees, and other forms of financial support from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Roche.Michel G Ison: received research support from Anolinx, Cellex, Chimerix, Crucell, GlaxoSmithKlein, NexBio and ViroPharma; provided paid consultation to Alios, Abbott, Crucell and Genentech/Roche; provided unpaid consultation to Adamas, BioCryst, Biota, Cellex, Clarassance, GlaxoSmithKlein, GenMarkDx, Romark, Toyama/MediVector, NexBio, Theraclone, Vertex and Visterra; participated to data and safety monitoring board for Biota and NexBio. The other authors declare that they have no competing interests. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

[^2]: Conceived and designed the experiments: SL FP GI VP ANC AR FV PAG SV. Analyzed the data: SL FP GI MGI PAG. Contributed reagents/materials/analysis tools: AR SV FV FP ANC. Wrote the paper: SL MGI YC GI.

[^3]: ¶ Members of Donor-Recipient Infection DRIn Collaborative Study Group is provided in the Acknowledgments.
